Faraday Pharmaceuticals, Inc.

Our Faraday team members had a productive day 1 at #TCT24. Please visit us at booth #1029 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure. Don’t forget to pick up a notebook and pen to jot down your thoughts!

We're heading to #washingtondc this weekend for the Transcatheter Cardiovascular Therapeutics (TCT) annual symposium #TCT24 organized by the Cardiovascular Research Foundation (CRF). This event is a fantastic opportunity to engage with investigators and colleagues involved in our ongoing Phase 3 clinical trial, #IocyteAMI3, cultivate new connections, and explore the latest innovations.  

With the #ESCCongress starting this weekend, we are looking forward to reconnecting with colleagues, presenting exciting science in our satellite symposium, and forming new relationships.

We will be hosting a satellite symposium during ESC Congress 2024 featuring Dr. Roxana Mehran (Icahn School of Medicine at Mount Sinai), Dr Matt Cavender, MD, MPH (University of North Carolina Hospitals – Chapel Hill), and Dr. Keith Channon (University of Oxford). Untapped and forgotten: controversies in the treatment of ischaemia-reperfusion injury.  https://lnkd.in/gK-5Kexr

We are excited to be participating in #ESCCongress in #London. Please visit booth G220 or attend our satellite symposium - Untapped and forgotten: controversies in the treatment of ischaemia-reperfusion injury (IRI) – to learn more about how Faraday is targeting IRI to reduce cardiac damage and heart failure. https://lnkd.in/gK-5Kexr

In case you missed our KOL Webinar, you can view it on demand here: https://lnkd.in/gFRxaePk

Join Faraday Pharmaceuticals, Inc. for a KOL webinar on Tues. July 30 at 11am ET with Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. Register here: https://bit.ly/4eXHjro

Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301 https://lnkd.in/g-Xm2u3n - 2,300 patients in trial enrolled ahead of schedule - 12-month follow up period underway, with topline data anticipated in 2H 2025 - Trial designed with 90% power to detect a 30% reduction in the primary outcome of heart failure and cardiovascular death after anterior STEMI #faradaypharma #IocyteAMI3 #FDY_5301

There are trailblazers among us in clinical operations, including clinical trial managers and clinical research associates, who help to forge the paths that lead to medical breakthroughs. #ClinicalTrialsDay #CTD2024

Today is National Fitness Day! See how some of our employees stay fit. Healthy muscle is important for overall health and well-being. Faraday is dedicated to helping patients live longer, better lives by developing drugs to prevent and treat cardiac and skeletal muscle loss, with the aim of improving clinical outcomes. #NationalFitnessDay